← Eichor
Condition: Castrate Resistance Prostate Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Castrate Resistance Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · 18 location(s) · Pathos AI, Inc. · NCT06785636Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/Phase 2 · 1 location(s) · University College, London · NCT07414940Working Out M0 Bipolar Androgen Therapy
Phase 2 · 12 location(s) · Australian and New Zealand Urogenital and Prostate Cancer Tr · NCT06594926Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Phase N/A · 2 location(s) · Santa Chiara Hospital · NCT06783127Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06200103A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re
Phase 1/Phase 2 · 82 location(s) · Merck Sharp & Dohme LLC · NCT06863272Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177
Phase N/A · 1 location(s) · Hannah Schaefer · NCT06720532Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Phase 2 · 1 location(s) · University of California, San Francisco · NCT05766371Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Phase 2 · 31 location(s) · Dendreon · NCT06134232A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · 281 location(s) · Celgene · NCT06764485Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Janssen Research & Development, LLC · NCT06800313Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Phase 3 · 30 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT03819101Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT06738303HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT07441889Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to C
Phase 3 · 174 location(s) · SWOG Cancer Research Network · NCT0647024364Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant
Phase 1/Phase 2 · 7 location(s) · Clarity Pharmaceuticals Ltd · NCT04868604Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Pro
Phase 2 · 3 location(s) · University of Washington · NCT06526299TT-702 in Patients With Advanced Solid Tumours.
Phase 1/Phase 2 · 3 location(s) · Cancer Research UK · NCT05272709A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · 83 location(s) · Pfizer · NCT03460977Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Phase 1/Phase 2 · 4 location(s) · Institute of Cancer Research, United Kingdom · NCT07002320Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Phase 4 · 2 location(s) · Brigham and Women's Hospital · NCT06099093A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Phase 1 · 25 location(s) · Astellas Pharma Global Development, Inc. · NCT04729114A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/Phase 2 · 14 location(s) · 858 Therapeutics, Inc. · NCT06395519Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT07090148TmPSMA-02 in mCRPC
Phase 1 · 1 location(s) · University of Pennsylvania · NCT06046040A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegal
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT07206056Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Phase 1/Phase 2 · 21 location(s) · Blue Earth Therapeutics Ltd · NCT05413850A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Phase 3 · 240 location(s) · Pfizer · NCT06629779
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.